Case todayNot read todayThesis-Break EngineThe case · mixed · Oct 15, 2026Own QTEX if early revenue turns into repeatable, higher-margin adoption before cash needs force punitive dilution.4 conditions1 holding · 3 weakeningNext resultsNot scheduledNo date filed yet

QTEX at a glance

The past year

Chart

+14.3% $1.12, close Nov 19

From the highest close
−63.6%
Vs the 200-day average
+13.0%
Nov 18, 2025Daily close, QTREX QuantumNov 19, 2026

Short interest

History

3.6M shares

Since the last report
−16.9%
Days to cover
1.0 day
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 14 – Nov 20

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

QTEX price history

Latest price$1.12Today−$0.00 (-0.00%)
QTEX -24.07%S&P 500 -7.02%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners.HoldingMateriality: High

    GAAP annual revenue was $289,000 in FY2025 after $0 in FY2024 and $0 in FY2023, indicating the first observable commercial or customer activity. If adoption becomes repeatable, the company can start building an operating business; if it remains pilot-like, the equity is mainly funding R&D with little proof of market pull.

    Watch: Hospitals or distributors treat the product as experimental and do not move beyond small pilots or evaluations.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue was $289,000 in FY2025 after $0 in FY2024 and $0 in FY2023, indicating the first observable commercial.

    Open source ↗
  • QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue.WeakeningMateriality: High

    GAAP annual gross profit turned positive in FY2025 but was only $2,000 on $289,000 of revenue. Revenue without gross margin will not fund R&D, sales support, regulatory work, or shareholder value creation.

    Watch: Contract manufacturing, installation, service, or warranty costs absorb most of the selling price as volume rises.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual gross profit turned positive in FY2025 but was only $2,000 on $289,000 of revenue.

    Open source ↗
  • QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders.WeakeningMateriality: Medium

    Cash was $3.159 million at FY2025 year-end, down from $5.111 million at FY2024 year-end. Even if the product eventually works, shareholders can still lose if the company must finance years of burn on punitive terms.

    Watch: Public-equity market access closes or Nasdaq liquidity weakens before commercial proof improves.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $3.159 million at FY2025 year-end, down from $5.111 million at FY2024 year-end.

    Open source ↗
  • Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses.WeakeningMateriality: Medium

    GAAP annual operating income was negative $13.623 million in FY2025, negative $11.267 million in FY2024, and negative $12.133 million in FY2023. A stable burn rate can be rational during product development, but it becomes value-destructive if it does not produce adoption, margin, or strategic validation.

    Watch: R&D, regulatory, and G&A spending rises to support a broader product roadmap before the first product proves market fit.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income was negative $13.623 million in FY2025, negative $11.267 million in FY2024, and negative $12.133 million in.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners. If adoption becomes repeatable, the company can start building an operating business; if it remains pilot-like, the equity is mainly funding R&D with little proof of market pull.

QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue. Revenue without gross margin will not fund R&D, sales support, regulatory work, or shareholder value creation.

QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders. Even if the product eventually works, shareholders can still lose if the company must finance years of burn on punitive terms.

Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses. A stable burn rate can be rational during product development, but it becomes value-destructive if it does not produce adoption, margin, or strategic validation.

All standing thesis claims
Original report summary

early revenue turns into repeatable, higher-margin adoption before cash needs force punitive dilution.

Evidence assessed Oct 15, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for QTREX Quantum

Where the evidence on QTREX Quantum disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 1 holding and 3 weakening.

Bull case: what the evidence supports

  • QTEX’s core product must move from initial or pilot demand into repeatable medical-instrument adoption by hospitals, distributors, or strategic partners.

    sec.gov ↗

Bear case: what the evidence questions

  • QTEX must prove that its medical-instrument sales carry product value and manufacturing leverage, not merely low-margin prototype or pilot revenue.

    sec.gov ↗

  • QTEX must secure enough capital, partnerships, or non-dilutive funding to bridge the commercialization period without transferring most future upside away from existing shareholders.

    sec.gov ↗

  • Management must convert a persistent development and overhead cost base into commercial proof rather than simply extending operating losses.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · QTREX Quantum

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

OptimistFi is watching QTREX Quantum. No break-condition checks are on record yet — they accumulate as new filings are checked.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Foreign issuer material report (6-K).

    QTREX Quantum filed an SEC report on 2026-10-09: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  2. Mixed
    Foreign issuer material report (6-K).

    QTREX Quantum filed an SEC report on 2026-10-01: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  3. Mixed
    Foreign issuer material report (6-K).

    QTREX Quantum filed an SEC report on 2026-09-24: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Hospitals or distributors treat the product as experimental and do not move beyond small pilots or evaluations.
  • Contract manufacturing, installation, service, or warranty costs absorb most of the selling price as volume rises.
  • Public-equity market access closes or Nasdaq liquidity weakens before commercial proof improves.
  • R&D, regulatory, and G&A spending rises to support a broader product roadmap before the first product proves market fit.

QTEX news

Loading headlines…

Financial statements

QTEX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

QTEX: quick answers

What is QTEX's short interest?
As of October 30, 2026, 3.6M QTEX shares were sold short, down 16.9% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. QTEX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.